Handelsavisen
prelaunch
Companies ›Healthcare ›CAI
CA
CAI — Nasdaq Diversified Medical Equipment & Supplies

Caris Life Sciences, Inc.

$15,85
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
LatestBank of Japan releases Consumption Activity Index to gauge private demand
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
4,5B USD
P/E
—
EV / Rev
5,0x
Div yield
—
Op margin
5,6 %
ROE
-11,5 %
Net margin
-8,4 %
Debt / equity
0,64
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$16,32
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Caris Life Sciences provides molecular profiling services and pharma research and development solutions, generating revenue primarily through genomic testing and data analytics for oncology and precision medicine applications.

Business. Caris Life Sciences, Inc. (CAI) is a health care company operating in the diversified medical equipment and supplies industry. The firm is headquartered in the United States and is listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY13 analysts
11 buy2 hold0 sell
Avg 12m price target30,46

Analyst recommendations

13 analysts · consensus Buy
Buy11
Hold2
Sell0
12-month price target
30,46
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
13 analysts · indicative
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-11,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

1
  • MARKETSBank of Japan releases Consumption Activity Index to gauge private demand2026-07-07

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CAI. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    This is the first analysis for Caris Life Sciences, Inc. (CAI), meaning there is no prior basis for computing material changes in the company's profile. Consequently, no significant shifts in operational metrics or strategic direction can be established relative to a previous baseline. The primary activity observed involves a major severity holder change for investor ID 587. Data indicates a modification in share count associated with this investor, with records showing a fluctuation between 9.0 shares and 1,635.0 shares as of March 31, 2026. These changes were detected on June 20 and June 21, 2026, respectively. The financial impact of these specific holdings is negligible, with the value of the 1,635 shares recorded at $0.029 million and the 9 shares at $0.000161 million. The weight of these positions in the investor's portfolio is similarly minute, ranging from approximately 0.00000009% to 0.000017%. Caris Life Sciences currently has 29 top holders but no reported analyst coverage, officer count, or index membership. Without analyst estimates or index inclusion, the company's market visibility remains limited to its existing holder base, and the recent minor adjustments in a single investor's position do not signal a broader shift in institutional sentiment.

    Signals & dispatch

    peak dispatch · 2026-07-07

    Composite-score breakdown

    Synthesis

    Business

    Caris Life Sciences, Inc. (CAI) is a health care company operating in the diversified medical equipment and supplies industry. The firm is headquartered in the United States and is listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    Caris Life Sciences maintains a robust liquidity position with $819.9 million in cash and equivalents against $381.4 million in long-term debt, resulting in a debt-to-equity ratio of 0.64 and a current ratio of 7.05. The company generated $32.9 million in operating cash flow and $22.5 million in free cash flow during Q1 2026, supporting its capital structure without immediate refinancing pressure. The balance sheet reflects total assets of $1.16 billion and total equity of $593.5 million, indicating a conservative leverage profile relative to its cash reserves.

    Profitability remains constrained as the company reports a net loss of $0.5 million on $216.2 million in revenue, yielding a negative return on equity of -11.47% and a negative return on assets of -5.86%. Operating income of $5.3 million represents a narrow margin, driven by high general and administrative expenses of $59.7 million and research and development costs of $31.3 million. The company trades at an EV/EBITDA of 59.62 and an EV/Revenue of 4.97, reflecting market expectations for future growth rather than current earnings power.

    This is the first analysis for Caris Life Sciences, Inc. (CAI), meaning there is no prior basis for computing material changes in the company's profile. Consequently, no significant shifts in operational metrics or strategic direction can be established relative to a previous baseline. The primary activity observed involves a major severity holder change for investor ID 587. Data indicates a modification in share count associated with this investor, with records showing a fluctuation between 9.0 shares and 1,635.0 shares as of March 31, 2026. These changes were detected on June 20 and June 21, 2026, respectively. The financial impact of these specific holdings is negligible, with the value of the 1,635 shares recorded at $0.029 million and the 9 shares at $0.000161 million. The weight of these positions in the investor's portfolio is similarly minute, ranging from approximately 0.00000009% to 0.000017%. Caris Life Sciences currently has 29 top holders but no reported analyst coverage, officer count, or index membership. Without analyst estimates or index inclusion, the company's market visibility remains limited to its existing holder base, and the recent minor adjustments in a single investor's position do not signal a broader shift in institutional sentiment.

    Key takeaways
    • Q1 2026 revenue surged 78.8% YoY to $216.2 million, driven by molecular profiling services.
    • Strong liquidity with $819.9 million in cash and a current ratio of 7.05 mitigates near-term solvency risks.
    • Profitability remains negative with a net loss of $0.5 million and ROE of -11.47%, reflecting high operating expenses.
    • Revenue concentration is extreme, with 97.5% derived from molecular profiling services.
    • Medium dilution risk persists due to significant stock-based compensation and potential future equity issuances.
    • Analyst sentiment is bullish with a mean price target of $27.42, implying substantial upside from the current $15.85 price.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights
    Open report →

    Revenue $216.2M; Operating income $5.3M.

    Revenue$216.2M
    Operating income$5.3M
    Net income-$510.0k
    Free cash flow$22.5M
    EPS—
    Operating cash flow$32.9M
    Financials
    Income statement
    Revenue$216.2M
    Gross profit—
    Operating income$5.3M
    Net income-$510.0k
    Margins
    Gross margin—
    Operating margin2.4%
    Net margin-0.2%
    FCF margin10.4%
    Balance sheet
    Total assets$1.16B
    Total liabilities$568.9M
    Total equity$593.5M
    Cash & equivalents$819.9M
    Long-term debt$381.4M
    Cash flow
    Operating cash flow$32.9M
    CapEx$10.3M
    Free cash flow$22.5M
    SBC$15.9M
    P&L flow · revenue → net income
    Revenue $216.2MOperating costs $210.9MTax $5.8MNet income $510.0k
    Highlights
    • ▍Revenue $216.2M
    • ▍Operating income $5.3M
    • ▍Net margin -0.2%

    Valuation FY

    Market price
    $15,85
    Market cap
    $4.48B
    Enterprise valueⓘ
    $4.04B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    5.0x
    EV / Op incomeⓘ
    89.5x
    EV / OCFⓘ
    48.6x
    P / Bⓘ
    7.8x
    P / Tangible bookⓘ
    7.8x
    Tangible book
    $574.1M
    Net cashⓘ
    $440.6M
    Current ratioⓘ
    7.0
    Debt / equityⓘ
    0.6
    ROAⓘ
    -5.9%
    ROEⓘ
    -11.5%
    Cash conversionⓘ
    -122.0%
    CapEx / revenueⓘ
    2.0%
    SBC / revenueⓘ
    8.6%
    Dilution ratioⓘ
    -0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)CAI 0,3% · rank #28 of 84

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs CAI · multiples and returns
    AB
    ABT—
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    — vs self
    Div yield
    2,4 %
    — vs self
    ROE
    12,5 %
    +24,0 vs self
    MD
    MDT—
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    — vs self
    Div yield
    3,4 %
    — vs self
    ROE
    9,7 %
    +21,2 vs self
    MD
    MDLN—
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    — vs self
    Div yield
    —
    — vs self
    ROE
    —
    — vs self
    SY
    SYK—
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    — vs self
    Div yield
    —
    — vs self
    ROE
    13,5 %
    +25,0 vs self
    BD
    BDX—
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    — vs self
    Div yield
    2,8 %
    — vs self
    ROE
    7,0 %
    +18,4 vs self
    HS
    HSIC—
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    — vs self
    Div yield
    —
    — vs self
    ROE
    3,0 %
    +14,4 vs self
    BA
    BAX—
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    —
    — vs self
    Div yield
    2,3 %
    — vs self
    ROE
    -15,4 %
    -4,0 vs self
    SO
    SOLV—
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    — vs self
    Div yield
    —
    — vs self
    ROE
    30,8 %
    +42,3 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,15
    Predicted surprise
    -0,00
    Beat probability
    45 %
    Analysts
    13
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-06 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate0,13
    Revenue—no estimate—no estimate1,0B USD
    Operating income—no estimate—no estimate64,6M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 3 %
    Probability
    3 %
    Base rate
    3 %
    Band
    —
    180-day horizon · target 2027-01-16 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution12 analysts
    Strong buy5
    Buy4
    Hold3
    Sell0
    Strong sell0
    12-month price target$27,42 · Median $27,50
    Low $21,00High $36,00
    Operating income · consensus64,6M USD
    EPS surprise
    −2 674,4 %
    reported vs consensus · miss
    Revenue surprise
    −19,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$21,00
    Mean$30,46
    Median$30,00
    High$38,00
    Spot$15,85
    +92.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskMedium
    Liquidity riskLow
    Filing-based flags
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    Op Margin5,6 %Above median
    Net Margin-8,4 %Below median
    ROE-11,5 %Below median
    Capex / Rev2,0 %Best in class
    D/E0,64Below median
    Cash Conv-1,22Bottom quartile

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    3 %
    Base rate
    3 %
    Band
    Low
    180-day horizon · target 2027-01-16 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 164 750 sh4 exercises3 insiders
    • CASTLEMAN PETER MDirector · Stock Option → Common StockDisposed 2 500 @ $18,60exercise · 2026-01-09
    • Power Luke ThomasSee Remarks · Stock Option → Common StockDisposed 37 500 @ $2,44exercise · 2025-12-11
    • Power Luke ThomasSee Remarks · Stock Option → Common StockDisposed 24 750 @ $2,44exercise · 2025-12-11
    • PHILLIPS T DANNYDirector · Stock Option → Common StockDisposed 100 000 @ $2,44exercise · 2025-09-11

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Caris Life Sciences, Inc. company facts · 2026-08-04
    • Caris Life Sciences, Inc. 10-Q 2026-05-08 · 2026-08-04
    • Caris Life Sciences, Inc. 10-K 2026-03-03 · 2026-08-04
    • Caris Life Sciences, Inc. 10-Q 2025-11-05 · 2026-08-04
    • Caris Life Sciences, Inc. 10-Q 2025-08-12 · 2026-08-04
    • allocator_boost (allocator) on CAI · 2026-08-04
    • Caris Life Sciences Inc Market data — analyst estimates · 2026-08-04
    • Caris Life Sciences Inc Market data — ESG · 2026-08-04

    Ownership & reference

    Top holders

    • T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,07 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,03 %$550M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,01 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$49M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$22M
    • Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,00 %$21M
    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,00 %$4M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$7M
    • MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,00 %$5M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$19M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$7M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$14M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$4M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$18M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$2M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$3M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling3 buys · 2 sellsnet -$1,0M13 insiders · last 365d
    • POSTE GEORGEDirector · Common StockOther 1 600 @ $15,62$25K · 2026-05-29
    • Knowles Jonathan Kenneth CharlesDirector · Common StockOther 1 600 @ $15,62$25K · 2026-05-29
    • Denton John RusselSee Remarks · Common StockOther 6 047 @ $15,25$92K · 2026-05-15
    • HALBERT DAVID DDirector, See Remarks, 10% owner · Common StockOther 40 712 @ $15,25$621K · 2026-05-15
    • Brille Brian JDirector, See Remarks · Common StockOther 13 987 @ $15,25$213K · 2026-05-15
    • Spetzler David BaxleyPresident · Common StockOther 13 856 @ $15,25$211K · 2026-05-15
    • Power Luke ThomasSee Remarks · Common StockOther 9 771 @ $15,25$149K · 2026-05-15
    • Vacirca Jeff LDirector · Common StockBought 31 050 @ $16,15$501K · 2026-05-11
    • HALBERT DAVID DDirector, See Remarks, 10% owner · Common StockOther 320 112 · 2026-03-06
    • Power Luke ThomasSee Remarks · Common StockOther 63 971 · 2026-03-06
    • Denton John RusselSee Remarks · Common StockOther 63 971 · 2026-03-06
    • Spetzler David BaxleyPresident · Common StockOther 83 162 · 2026-03-06
    • Brille Brian JDirector, See Remarks · Common StockOther 83 162 · 2026-03-06
    • PHILLIPS T DANNYDirector · Common StockOther 3 739 @ $20,06$75K · 2026-02-26
    • Vacirca Jeff LDirector · Common StockOther 2 492 @ $20,06$50K · 2026-02-26
    • CASTLEMAN PETER MDirector · Common StockOther 5 509 @ $20,06$111K · 2026-02-26
    • Fredrickson David PaulDirector · Common StockOther 2 492 @ $20,06$50K · 2026-02-26
    • HALBERT JONDirector · Common StockOther 2 492 @ $20,06$50K · 2026-02-26
    • Minor LloydDirector · Common StockOther 2 492 @ $20,06$50K · 2026-02-26
    • CASTLEMAN PETER MDirector · Common StockOther 2 500 @ $18,60$46K · 2026-01-09
    • Brille Brian JDirector, See Remarks · Common StockOther 650 · 2025-12-11
    • Power Luke ThomasSee Remarks · Common StockOther 24 750 @ $2,44$60K · 2025-12-11
    • Power Luke ThomasSee Remarks · Common StockOther 37 500 @ $2,44$92K · 2025-12-11
    • Power Luke ThomasSee Remarks · Common StockSold 60 850 @ $26,56$1,6M · 2025-12-11
    • Power Luke ThomasSee Remarks · Common StockSold 1 400 @ $27,16$38K · 2025-12-11

    Short positioning

    11.7Mshares short-17.2% vs prior
    3.39days to cover
    32.2%short of daily vol
    14.4Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CAICanonical
    Nasdaq · USD

    Intel & risk

    PredictorBeat prob45 %Surprise-0,00M&A prob3 %Full forecast →
    peak dispatch · 2026-07-07
    OSINT findings
    Dilution riskMedium
    Liquidity riskLow
    Source documents mention dilution or offering risk.

    Evidence & claims

    From filings & derived data
    • Current ratio (FY 2025-12-31): 7.85xDerived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 227.5%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 92.6%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 75.8%Derived (calculated)
    • Return on assets (FY 2025-12-31): -6.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 123.1%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 1.4%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 69.8%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 1,145.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 97.0%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 69.8%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.95xDerived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -11.7%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 133.9%Derived (calculated)
    • Return on equity (FY 2025-12-31): -11.8%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -10.8%Derived (calculated)
    • Net margin (FY 2025-12-31): -8.4%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 117.5%Derived (calculated)
    • Revenue (annual): USD 812.03MSEC XBRL filing
    • Long-term debt (annual): USD 378.45MSEC XBRL filing
    • Shareholders' equity (annual): USD 577.31MSEC XBRL filing
    • Pre-tax income (annual): USD -68.09MSEC XBRL filing
    • Shares outstanding (annual): 282.53MSEC XBRL filing
    • R&D expense (annual): USD 101.58MSEC XBRL filing
    Showing 24 of 57 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-05 00:00 UTCTRANSCRIPTUpcomingEarnings call — Q3 2026
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-21 02:57 UTCHOLDER2 institutional position changes flagged (2 major)
    2026-06-05FILING8-K filing →
    2026-05-29 00:00 UTCINSIDER8 insider transactions — 2026-05 · net sell $735k
    2026-05-29INSIDERPOSTE GEORGE transacted 1.6k sh — Director ~$25k
    2026-05-29INSIDERKnowles Jonathan Kenneth Charles transacted 1.6k sh — Director ~$25k
    2026-05-15INSIDERDenton John Russel transacted 6.0k sh — See Remarks ~$92k
    2026-05-15INSIDERHALBERT DAVID D transacted 40.7k sh — Director, See Remarks, 10% owner ~$621k
    2026-05-15INSIDERBrille Brian J transacted 14.0k sh — Director, See Remarks ~$213k
    2026-05-15INSIDERSpetzler David Baxley transacted 13.9k sh — President ~$211k
    2026-05-15INSIDERPower Luke Thomas transacted 9.8k sh — See Remarks ~$149k
    2026-05-11INSIDERVacirca Jeff L bought 31.1k sh — Director ~$501k
    2026-05-08FILING10-Q filing →
    2026-05-07FILING8-K filing →
    2026-04-23FILINGDEF 14A filing →
    2026-04-02FILING8-K filing →
    2026-03-06 00:00 UTCINSIDER5 insider transactions — 2026-03
    2026-03-06INSIDERHALBERT DAVID D transacted 320.1k sh — Director, See Remarks, 10% owner
    2026-03-06INSIDERPower Luke Thomas transacted 64.0k sh — See Remarks
    2026-03-06INSIDERDenton John Russel transacted 64.0k sh — See Remarks
    2026-03-06INSIDERSpetzler David Baxley transacted 83.2k sh — President
    2026-03-06INSIDERBrille Brian J transacted 83.2k sh — Director, See Remarks
    2026-03-03FILING10-K filing →
    2026-02-26 00:00 UTCINSIDER6 insider transactions — 2026-02 · net buy $385k
    2026-02-26FILING8-K filing →
    2026-02-26INSIDERPHILLIPS T DANNY transacted 3.7k sh — Director ~$75k
    2026-02-26INSIDERVacirca Jeff L transacted 2.5k sh — Director ~$50k
    2026-02-26INSIDERCASTLEMAN PETER M transacted 5.5k sh — Director ~$111k
    2026-02-26INSIDERFredrickson David Paul transacted 2.5k sh — Director ~$50k
    2026-02-26INSIDERHALBERT JON transacted 2.5k sh — Director ~$50k
    2026-02-26INSIDERMinor Lloyd transacted 2.5k sh — Director ~$50k
    2026-01-12FILING8-K filing →
    2026-01-09 00:00 UTCINSIDER2 insider transactions — 2026-01 1 derivative
    2026-01-09INSIDERCASTLEMAN PETER M transacted 2.5k sh — Director ~$46k
    2026-01-09INSIDERCASTLEMAN PETER M disposed of 2.5k sh Stock Option — Director
    2025-12-11 00:00 UTCINSIDER8 insider transactions — 2025-12 · net sell $1.5M 2 derivative
    2025-12-11INSIDERBrille Brian J transacted 650 sh — Director, See Remarks
    2025-12-11INSIDERPower Luke Thomas transacted 24.8k sh — See Remarks ~$60k
    Showing the 40 most recent of 52 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage